Polymeric Propranolol Nanoparticles for Intraocular Delivery: Formulation, Characterization, and Vitreous...

Area of Science:

• Ophthalmology
• Biomaterials Science
• Pharmacology

Background:

• Intravitreal propranolol shows promise for retinal neovascularization.
• Rapid drug clearance and short half-life limit propranolol's efficacy.
• Developing strategies to prolong ocular drug residence time is crucial.

Purpose of the Study:

• To investigate the use of poly (lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) to extend propranolol's residence time in the vitreous.
• To evaluate the potential of propranolol-loaded NPs for treating choroidal neovascularization.

Main Methods:

• PLGA NPs were fabricated using a modified double emulsion solvent evaporation method.
• Characterization included size, PDI, surface imaging, in vitro release, cytotoxicity, and uptake studies.
• In vivo pharmacokinetic studies in rabbits involved intravitreal injection and HPLC analysis of drug concentrations.

Main Results:

• Spherical NPs (approx. 230 nm) with 10% drug loading were achieved.
• Confocal microscopy confirmed NP presence in the posterior segment for five days post-injection.
• In vivo studies showed a twofold reduction in propranolol's vanishing rate with NPs compared to the free drug.

Conclusions:

• PLGA NPs effectively prolong the existence of propranolol in ocular tissues.
• This NP-based delivery system presents a viable approach for treating posterior segment neovascularization.